# Rifaximin on Visceral Hypersensitivity

> **NCT03462966** · PHASE2 · TERMINATED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 4 (actual)

## Conditions studied

- Visceral Hypersensitivity
- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT03462966
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-01
- **Primary completion:** 2021-11-19
- **Final completion:** 2021-11-19
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** recruitment challenges
- **Last updated:** 2022-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03462966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03462966, "Rifaximin on Visceral Hypersensitivity". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03462966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*